Lupus Research Update – 2 Positive Lupus Trials published in December
Dr. Ailda Nika shared this article wtih readers. Check lupusil.org for more “Latest News” for the lupus community.
Breaking news in the Lupus World!
While there is substantial unmet need for people with lupus given the limitations of therapeutic agents, two positive trials just came out in the month of December.
First Biogen, a pharmaceutical company based in Cambridge, Massachuset that is working on a drug for cutaneous lupus, announces that LILAC 2 study met its primary endpoint demonstrating significant reduction of disease activity in patients with skin involvement.
Cutaneous lupus is a chronic autoimmune disease where the body’s immune system attacks healthy skin, often causing rashes and other skin lesions, which can become potentially painful, disfiguring and can interfere with someone’s quality of life leading to anxiety, depression and psycho-social impact.
This study evaluated a biologic agent, fully humanized antibody targeting the potential cells responsible for causing skin disease with or without other manifestations and it demonstrated a significantly greater reduction of disease area and severity activity index at week 16 compared to placebo.
In addition improvement in other disease components were consistently observed across multiple other analyzed endpoints.
The safety and tolerability profile of this new drug supports its continued development, and there is hope for a very powerful agent in the pipeline that very soon might become clinically available.
Second Aurina Pharmaceuticals, another Canadian pharmaceutical company, announces very positive , top-line Phase 3 study results demonstrating Valclosporin a therapeutic agent for lupus nephritis , active disease affecting the kidney, superiority over standard of care.
The study met all the primary and secondary end points more importantly achieving complete remission in a statistically greater number of patients who received Valclosporine in addition to the other drugs used as a standard of care.
These are some of the news that lupus community has been waiting for years in order to raise hopes that soon doctors might be able to positively impact the quality of lives of over more than five million affected by lupus worldwide.